文献速递艾滋病与性传播感染

法国2006-2017年新诊断HIV-1感染儿童的耐药流行率:对一线治疗策略敏感性的影响

Prevalence of drug resistance in children recently diagnosed with HIV-1 infection in France (2006-17): impact on susceptibility to first-line strategies.
PubMed 文献 · J Antimicrob Chemother · 2018-01-01

该研究分析了法国2006-2017年84例新诊断HIV-1感染儿童的传播性耐药(TDR)流行率,采用2009年Stanford突变列表和2017年法国ANRS算法评估。结果显示TDR频率为8.3%(7/84,Stanford列表)和16.7%(14/84,两者联合),作者建议优先选用基于蛋白酶抑制剂(PI)或多替拉韦的方案而非基于NNRTI的方案治疗新诊断HIV感染儿童。

要点

  • 84例新诊断HIV-1感染儿童中,TDR频率为8.3%(7/84,Stanford列表)和16.7%(14/84,Stanford联合ANRS算法)。
  • PI相关耐药突变率为0%,NRTI为3.6%,依非韦伦/奈韦拉平为6.0%,依曲韦林/利匹韦林为11.9%,多拉韦林为2.4%。
  • 作者建议优先选用基于PI或多替拉韦的方案而非基于NNRTI的方案治疗新诊断HIV感染儿童。

核心结论

  • 法国儿童中NRTI和NNRTI相关TDR比例低于低收入和中等收入国家。
  • 作者建议优先选用基于PI或多替拉韦的方案而非基于NNRTI的方案治疗新诊断HIV感染儿童,即使无既往抗逆转录病毒预防暴露史。

研究设计与样本

  • 研究纳入法国2006-2017年新诊断HIV-1感染的84例儿童。
  • 使用2009年Stanford突变列表和2017年法国ANRS算法鉴定耐药相关突变(RAMs)。
  • 对每种一线推荐抗逆转录病毒治疗组合估算基因型敏感性评分(GSS)。

主要发现

  • 患者主要经母婴传播(MTCT)感染(73/84;86.9%),仅18例儿童(垂直感染患者的24.7%)既往暴露于MTCT抗逆转录病毒预防。
  • 非B亚型占90.5%(76/84)。
  • TDR频率为8.3%(7/84,2009年Stanford列表)和16.7%(14/84,Stanford列表联合2017年ANRS算法)。
  • PI、NRTI、依非韦伦/奈韦拉平、依曲韦林/利匹韦林和多拉韦林相关RAMs的流行率分别为0%、3.6%、6.0%、11.9%和2.4%。
  • 单一、双重和三类耐药分别占15.5%、1.2%和0%;3/60(5%)株具有整合酶抑制剂(INI)相关RAMs(孤立E157Q突变,主要可能影响对拉替拉韦/埃替拉韦而非多替拉韦的敏感性)。

关键数值与推荐

  • TDR频率:8.3%(7/84,2009年Stanford列表)和16.7%(14/84,Stanford列表联合2017年ANRS算法)。
  • RAMs流行率:PI 0%、NRTI 3.6%、依非韦伦/奈韦拉平6.0%、依曲韦林/利匹韦林11.9%、多拉韦林2.4%。
  • 单一、双重、三类耐药分别占15.5%、1.2%、0%。
  • INI相关RAMs:3/60(5%)株,为孤立E157Q突变。
  • GSS=3比例:PI方案≥97.6%、INI方案≥94.1%、依非韦伦/奈韦拉平方案≥92.9%、利匹韦林方案≥89.3%。

临床怎么用

  • 作者建议优先选用基于PI或多替拉韦的方案而非基于NNRTI的方案治疗新诊断HIV感染儿童,即使无既往抗逆转录病毒预防暴露史。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To describe the prevalence of transmitted drug resistance (TDR) among 84 children newly diagnosed with HIV in France in 2006-17. METHODS: HIV-1 resistance-associated mutations (RAMs) were characterized using both the 2009 Stanford list of mutations and the 2017 French National Agency for AIDS Research (ANRS) algorithm. A genotypic susceptibility score (GSS) was estimated for each first-line recommended ART combination. RESULTS: Patients were mainly infected through mother-to-child transmission (MTCT) (73/84; 86.9%), but only 18 children (24.7% of vertically infected patients) were previously exposed to antiretroviral prophylaxis from MTCT. Non-B variants were identified in 90.5% (76/84) of patients. The frequency of TDR was 8.3% (7/84) using the 2009 Stanford list and 16.7% (14/84) using both the Stanford list and the 2017 ANRS algorithm. The prevalence of PI-, NRTI-, efavirenz/nevirapine-, etravirine/rilpivirine- and doravirine-associated RAMs was 0%, 3.6%, 6.0%, 11.9% and 2.4%, respectively. Single-, dual- and triple-class resistance was present in 15.5%, 1.2% and 0% of cases, respectively. Additionally, 3/60 (5%) strains had integrase inhibitor (INI)-related RAMs (an isolated E157Q mutation, which could mostly affect the susceptibility to raltegravir/elvitegravir rather than that to dolutegravir). Among the 18 children exposed to MTCT prophylaxis, RAMs were identified in only 1 case (5.6%). The proportion of fully active combinations (GSS = 3) was ≥97.6%, ≥94.1%, ≥92.9% and ≥89.3% for PI-, INI-, efavirenz/nevirapine- and rilpivirine-based regimens, respectively. CONCLUSIONS: The proportion of NRTI- and NNRTI-related TDR in children is lower in France than in low- and middle-income countries. However, we suggest favouring PI- or dolutegravir- over NNRTI-based combinations to treat newly diagnosed HIV-infected children, even in the absence of previous exposure to antiretroviral prophylaxis of MTCT.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Frange P, Avettand-Fenoel V, Veber F, et al. Prevalence of drug resistance in children recently diagnosed with HIV-1 infection in France (2006-17): impact on susceptibility to first-line strategies. J Antimicrob Chemother. 2018. PMID: 29846602. doi:10.1093/jac/dky203

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。